KatarzynaJJamiesonMD

Oncology • Chapel Hill, NC

Physician

Join to view full profile

Dr. Jamieson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jamieson's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 984-974-0000

Fax+1 919-966-7772

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1995 - 1999
Advocate Health Care/Advocate Illinois Masonic Medical CenterResidency, Internal Medicine, 1992 - 1995
Wroclaw Medical UniversityClass of 1987

Certifications & Licensure

NC State Medical License 2012 - 2025
IA State Medical License 2008 - 2014
FL State Medical License 1999 - 2013
IL State Medical License 1992 - 1999
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Start of enrollment: 2006 Sep 01
Terminated
Phase 2
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens Start of enrollment: 2006 Jul 01
Terminated
Phase 2
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Start of enrollment: 2016 Dec 01
Completed
Phase 2
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis Start of enrollment: 2023 Dec 08
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Randomized Phase III SIERRA Trial ofI-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow
Journal of Clinical Oncology. 2024-09-19
3 citations
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30lymphoma: a phase 1 study.
Natalie S Grover, George Hucks, Marcie L Riches, Anastasia Ivanova, Dominic T Moore
The Lancet. Haematology. 2024-05-01
18 citations
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow D...
Bronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, Brent R Logan, Farhad Khimani
Transplantation and Cellular Therapy. 2023-03-01

Abstracts/Posters

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
Katarzyna Jamieson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
Katarzyna Jamieson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019